MARKET

GOVX

GOVX

Geovax Labs Inc
NASDAQ
1.500
-0.020
-1.32%
After Hours: 1.560 +0.06 +4.00% 19:33 04/19 EDT
OPEN
1.635
PREV CLOSE
1.520
HIGH
1.635
LOW
1.500
VOLUME
19.41K
TURNOVER
0
52 WEEK HIGH
11.82
52 WEEK LOW
1.450
MARKET CAP
3.46M
P/E (TTM)
-0.1050
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at GOVX last week (0408-0412)?
Weekly Report · 4d ago
WHO's Tedros Adhanom Ghebreyesus Posts On X "In #DRC alone, more than 4500 cases of #mpox and almost 300 deaths have been reported this year. That is triple the number reported at this time last year. The recent surge in cases and deaths among children is of particular concern, along with the re-emergence of Clade One in central Africa...."
Benzinga · 04/11 14:09
Weekly Report: what happened at GOVX last week (0401-0405)?
Weekly Report · 04/08 11:33
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Protara Therapeutics (NASDAQ:TARA) stock increased by 40.3% to $5.64 during Friday's pre-market session. Candel Therapeutic shares moved upwards by 25.93% during the session. The company's market cap stands at $236.5 million.
Benzinga · 04/05 12:09
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
Presentation Made During the 24th Annual World Vaccine Congress in Washington, DC. GeoVax Labs, Inc. Presented data on GEO-CM04S1, the Company's next-generation Covid-19 vaccine candidate. The company is developing immunotherapies and vaccines against cancers and infectious diseases.
Barchart · 04/04 11:30
Weekly Report: what happened at GOVX last week (0325-0329)?
Weekly Report · 04/01 11:30
GeoVax To Present Data On GEO-CM04S1, A Next Generation Covid-19 Vaccine, At The World Vaccine Congress
GeoVax's Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-CM04S1, the Company's next-generation Covid-19 vaccine candidate. The vaccine is designed to induce both antibody and T cell responses to the SARS-CoV-2 variant of the virus. The presentation will be at the 24th Annual World Vaccine Congress in Washington, DC on April 4, 2024.
Benzinga · 03/28 13:06
Weekly Report: what happened at GOVX last week (0318-0322)?
Weekly Report · 03/25 11:33
More
About GOVX
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.

Webull offers Geovax Labs Inc stock information, including NASDAQ: GOVX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GOVX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GOVX stock methods without spending real money on the virtual paper trading platform.